1-11 of 11
Daniel Deangelo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael W. Deininger, Yeow Tee Goh, Jeroen J.W.M. Janssen, Moshe Talpaz, Valle Gomez G De Soria, Philipp le Coutre, Francois-Xavier Mahon, Daniel Deangelo, Shruti Kapoor, Gessami Sanchez-Olle, Meng Cao, Nithya Agrawal, Timothy P Hughes
Journal: Blood
Blood (2024) 144 (Supplement 1): 1765.
https://doi.org/10.1182/blood-2024-209537
Published: 2024
Journal Articles

Analysis of Avapritinib Clinical Trial Data Generates a Highly Accurate Predictive Model for Advanced Systemic Mastocytosis Versus Indolent Systemic Mastocytosis Based on Peripheral Blood Testing

Ben Lampson, Aaron Zakharyan, Shai O. Shimony, Hongliang Shi, Daniel Deangelo
Journal: Blood
Blood (2024) 144 (Supplement 1): 107.
https://doi.org/10.1182/blood-2024-210181
Published: 2024
Journal Articles

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Steven M. Devine, MD, Kouros Owzar, PhD, William Blum, MD, Daniel DeAngelo, MD, Richard M. Stone, MD, Jack W Hsu, MD, Richard E. Champlin, Yi-Bin A. Chen, MD, Ravi Vij, MD, James L Slack, MD, Robert J. Soiffer, MD, Richard A. Larson, MD, Thomas C. Shea, MD, Vera Hars, MS, Elizabeth Bennett, BS, Sada Spangle, Sergio A Giralt, MD, Shelly L. Carter, ScD, Mary M. Horowitz, MD, MS, Charles Linker, MD, Edwin P Alyea, III, MD
Journal: Blood
Blood (2012) 120 (21): 230.
https://doi.org/10.1182/blood.V120.21.230.230
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012
Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, Martin C Muller, MD, Carlo Gambacorti-Passerini, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3763.
https://doi.org/10.1182/blood.V120.21.3763.3763
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Hagop M. Kantarjian, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John Goldman, DM, FRCP, FRCPath, FMedSci, Neil Shah, MD, PhD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 915.
https://doi.org/10.1182/blood.V120.21.915.915
Published: 2012
Journal Articles

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Daniel DeAngelo, MD, Wendy Stock, MD, Stephen Petersdorf, MD, Shaw-Ling Wang, Angela Volkert, Erik Vandendries, Anjali Advani, MD
Journal: Blood
Blood (2012) 120 (21): 2612.
https://doi.org/10.1182/blood.V120.21.2612.2612
Published: 2012
Journal Articles

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Clinical Trials & Observations
Francis Giles, Norbert Vey, Daniel DeAngelo, Karen Seiter, Wendy Stock, Robert Stuart, Darinka Boskovic, Arnaud Pigneux, Martin Tallman, Joseph Brandwein, Jonathan Kell, Tadeusz Robak, Peter Staib, Xavier Thomas, Ann Cahill, Maher Albitar, Susan O'Brien
Journal: Blood
Blood (2009) 114 (19): 4027–4033.
https://doi.org/10.1182/blood-2009-06-229351
Published: 2009
Journal Articles

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Irene M. Ghobrial, M.D., Stacey Chuma, RN, Amy Sam, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Brianna Harris, Jacob Soumerai, Diane Warren, Eric Jacobsen, MD, Daniel DeAngelo, MD, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Thomas E. Witzig, MD, Steven P. Treon, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1011.
https://doi.org/10.1182/blood.V112.11.1011.1011
Published: 2008
Journal Articles

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Renee Leduc, Marybeth Nelson, Xavier Leleu, Eric Jacobsen, Ann LaCasce, Daniel DeAngelo, David Fisher, Jennifer R. Brown, Robert Schlossman, Diane Warren, Jacob Soumerai, Kelly O’Connor, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson, Thomas E. Witzig, Steven P. Treon
Journal: Blood
Blood (2007) 110 (11): 4496.
https://doi.org/10.1182/blood.V110.11.4496.4496
Published: 2007
Journal Articles

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small
Journal: Blood
Blood (2006) 108 (10): 3477–3483.
https://doi.org/10.1182/blood-2006-04-015743
Published: 2006